Caylan R, Yilmaz G, Sucu N, Bayraktar O, Aydin K, Kaklikkaya N, Aydin F, Köksal I
Karadeniz Teknik Universitesi Tip Fakültesi, infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Anabilim Dali, Trabzon.
Mikrobiyol Bul. 2005 Jan;39(1):25-33.
Stenotrophomonas maltophilia is a nosocomial pathogen of increasing importance. In our study, 190 S. maltophilia strains isolated from 153 hospitalized patients between January 2000-April 2004, at Farabi Hospital at Medical School of Karadeniz Technical University, were prospectively evaluated. Of these patients 67.9% were clinically compatible with nosocomial infection, and 32% were considered as colonization. It was observed that rate of infection had a tendency to increase one year of age and above 50 years of age. Nosocomial infection and/ or colonization with S. maltophilia was detected in 19.7 +/- 15.2 (1-89) days after hospitalization. The clinical manifestations were bacteremia (36.5%), pneumoniae (28.8%), urinary system infection (12.5%), surgical site infection (11.5%) and peritonitis (6.7%). The bacteremia episodes were associated with central venous catheter in 37.3% (19/51), ventilator associated pneumonia in 11.7% (6/51), urinary system infection in 7.8% (4/51), peritonitis in 3.9% (2/51), and surgical site infection in 1.9% (1/51) of cases. Nineteen patients (37.3%) had no apparent primary source of infection. Higher APACHE II score, longer duration of hospitalization and prior extended-spectrum antibiotic therapy were observed in most of the patients. Antibiotic susceptibility testing revealed that, the most effective antibiotics against the isolates were trimethoprim-sulfamethoxazole (94%), ticarcillin/clavulanate (79%) and ciprofloxacin (53.5%). Crude mortality rate in the patients with S. maltophilia infections was found to be 25%. In addition, it was observed that proper antibiotic treatment had protective role against mortality (14.6% vs 63.6%; OR = 0.1, Cl95 0.12-0.42, P = 0.000). It can be concluded that to prevent infections due to S. maltophilia , effective infection control programmes and rational antibiotic use policies should be established promptly.
嗜麦芽窄食单胞菌是一种日益重要的医院病原体。在我们的研究中,对2000年1月至2004年4月间从卡拉德尼兹技术大学医学院法拉比医院153名住院患者中分离出的190株嗜麦芽窄食单胞菌菌株进行了前瞻性评估。这些患者中,67.9%临床上符合医院感染,32%被视为定植。观察到感染率在1岁及50岁以上人群中有上升趋势。嗜麦芽窄食单胞菌医院感染和/或定植在住院后19.7±15.2(1 - 89)天被检测到。临床表现为菌血症(36.5%)、肺炎(28.8%)、泌尿系统感染(12.5%)、手术部位感染(11.5%)和腹膜炎(6.7%)。菌血症发作与中心静脉导管相关的占37.3%(19/51),呼吸机相关性肺炎相关的占11.7%(6/51),泌尿系统感染相关的占7.8%(4/51),腹膜炎相关的占3.9%(2/51),手术部位感染相关的占1.9%(1/51)。19名患者(37.3%)没有明显的原发性感染源。大多数患者观察到较高的急性生理与慢性健康状况评分系统(APACHE II)评分、较长的住院时间和先前的广谱抗生素治疗。抗生素敏感性测试显示,对分离株最有效的抗生素是复方新诺明(94%)、替卡西林/克拉维酸(79%)和环丙沙星(53.5%)。嗜麦芽窄食单胞菌感染患者的粗死亡率为25%。此外,观察到适当的抗生素治疗对死亡率有保护作用(14.6%对63.6%;比值比 = 0.1,95%置信区间0.12 - 0.42,P = 0.000)。可以得出结论,为预防嗜麦芽窄食单胞菌引起的感染,应迅速建立有效的感染控制计划和合理的抗生素使用政策。